February 23, 2021 + Jessica Di Palo
3 Min read
What you need to know when pitching to a healthtech investor!
Pitching a healthtech investor is not an easy exercise for many entrepreneurs because you may never get a second chance to make a good first impression!
When you are starting a presentation about your company, focus on setting the scene by describing the current environment with its related challenges and pain points. Then present the unmet medical need, which must be clearly identified in order to demonstrate how you are solving the issue and why your product is better than its competitors.
Entrepreneurs must be able to present the value their company is adding to stakeholders because healthcare is a value-based market where only ‘must-have’ solutions can survive and because insurance will never pay for ‘nice-to-have products’. The general constraint on healthcare spending continues to accentuate this fact.
The goal is to show that your solution has a competitive advantage and you are able to secure it with key assets such as (clinical) validation data, patents, a proprietary data set to train your machine learning or an existing customer network. These kinds of assets add a lot of value to your company because they de-risk the investment in the investor’s eyes.
A good value proposition with a sizeable cash amount is not equal to success without cornerstones demonstrating a feasible plan and the right capabilities to execute the vision. Your roadmap should include value inflection points, usually defined by target milestones, their related activities, and how the money raised is allocated over time.
This planning exercise is important and often underestimated by companies, but it provides clarity for an investor about the management’s view. The team must demonstrate technical knowledge and expertise, but also sales and marketing skills.
Exit scenarios need to be addressed with potential future buyers and timelines because most venture capital funds are closed-ended (normally 8-10 years lifespan), which means they need to be liquidated in a certain timeframe. Keep in mind that exit triggers the venture capitalist’s strategy!
The first interaction between an entrepreneur and an healthtech investor will start at two different sides of the table but might end up side by side, in the same boat. At the end of the journey, transparency, honesty, and open communication are essential for rowing faster together.
We wish you a lot of success when pitching to your next healthtech investor!
written by Dr. Christoph Kausch – Managing partner at MTIP.
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II
How to pitch to a healthtech Investor
MTIP invests in Koa Health to make mental health treatment more accessible
New investment in Koa Health
MTIP scored fantastic grades in the UNPRI assessment report of 2020
UNPRI Report grades 2020
4 Health VCs Share Their Business Priorities and What is Next
MTIP invests in Trialbee
New investment in Trialbee
TytoCare closes $50 million round as the demand for telehealth accelerates
TytoCare closes new round
The digital healthtech sector is expanding – and so are we!
Two new empolyees start in April
MTIP has sucessfully exited Blueprint Genetics
Blueprint exit January 2020
New MTIP investment in Oviva
New investment in Oviva
Whitepaper: A positive prognosis for the future of healthtech
Our first Whitepaper
Elite Summit 2019 – Interview with our Managing Partner Christoph Kausch
Elite Summit 2019
MTIP Healthcare Clinic 2019
Healthcare clinic 2019
New MTIP investment in Cynerio
New investment in Cynerio
MTIP invests in Lumeon Ltd.
New investment in Lumeon
Magenverkleinerung mit der Handnähmaschine
Nitinotes news paper article
New MTIP investment in Quanta Dialysis Technologies
New investment in Quanta
MTIP’s Healthcare Clinic 2018
Healthcare Clinic 2018
Interview with Christoph Kausch in biotechandmoney
New MTIP investment – Nitinotes Series A Round
New investment in Nitinotes
New investment in an Israeli based digital health company TytoCare
New investment in TytoCare
MTIP joins United Nations-supported Principles for Responsible Investments
MTIP signs Principles for Responsible Investments
MTIP invests in Blueprint Genetics
new investment in Blueprint Genetics